Whereas safety and efficacy of HPV vaccines in healthy women have been shown in several randomised controlled clinical trials and in post marketing analyses, only few data exist in patients affected by autoimmune diseases. These issues are significant as autoimmune conditions are recognised as a risk factor for the persistence of HPV infection. Herein we review and systematise the existing literature to assess immunogenicity and safety of HPV vaccination in patients with autoimmune diseases, including systemic lupus erythematosus and juvenile idiopathic arthritis. The results of our literature revision suggest that the HPV vaccines are efficacious and safe in most of the patients affected by autoimmune diseases. Yet, some points of concern remain to be tackled, including the effects of concomitant therapies, the risk of disease exacerbation and the cost-effectiveness of such immunisation programmes in these populations.
Immunogenicity and safety of the human papillomavirus vaccine in patients with autoimmune diseases : a systematic review / P. Pellegrino, S. Radice, E. Clementi. - In: VACCINE. - ISSN 0264-410X. - 33:30(2015 Jul 09), pp. 3444-3449. [10.1016/j.vaccine.2015.05.041]
Immunogenicity and safety of the human papillomavirus vaccine in patients with autoimmune diseases : a systematic review
P. PellegrinoPrimo
;S. RadiceSecondo
;E. ClementiUltimo
2015
Abstract
Whereas safety and efficacy of HPV vaccines in healthy women have been shown in several randomised controlled clinical trials and in post marketing analyses, only few data exist in patients affected by autoimmune diseases. These issues are significant as autoimmune conditions are recognised as a risk factor for the persistence of HPV infection. Herein we review and systematise the existing literature to assess immunogenicity and safety of HPV vaccination in patients with autoimmune diseases, including systemic lupus erythematosus and juvenile idiopathic arthritis. The results of our literature revision suggest that the HPV vaccines are efficacious and safe in most of the patients affected by autoimmune diseases. Yet, some points of concern remain to be tackled, including the effects of concomitant therapies, the risk of disease exacerbation and the cost-effectiveness of such immunisation programmes in these populations.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S0264410X15006933-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
607.91 kB
Formato
Adobe PDF
|
607.91 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.